Cargando…

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review

OBJECTIVE: To aid trialists, systematic reviewers and others, we evaluated the degree of standardisation of control measure reporting that has occurred in atrial fibrillation (AF) and venous thromboembolism (VTE) studies since 2000; and attempted to determine whether the prior recommendation of repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mearns, Elizabeth S, Hawthorne, Jessica, Song, Ju-Sung, Coleman, Craig I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067815/ https://www.ncbi.nlm.nih.gov/pubmed/24951111 http://dx.doi.org/10.1136/bmjopen-2014-005379

Ejemplares similares

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression
por: Mearns, Elizabeth S, et al.
Publicado: (2014)

Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2021)

Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis
por: Gao, Xinxing, et al.
Publicado: (2022)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
por: Wu, Xiaojuan, et al.
Publicado: (2021)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Geriatric Conditions and Prescription of Vitamin K Antagonists vs. Direct Oral Anticoagulants Among Older Patients With Atrial Fibrillation: SAGE-AF
por: McManus, David D., et al.
Publicado: (2019)

Association of Direct Oral Anticoagulants vs. Vitamin K Antagonists With Fractures in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
por: Wu, Xiaojuan, et al.
Publicado: (2021)

Effects of direct oral anticoagulants vs. vitamin K antagonists on acute kidney injury in patients with atrial fibrillation: A systematic review
por: Ren, Chengfa, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting
por: Wu, Yue, et al.
Publicado: (2021)

Prevalence, risk factors, and prediction of inappropriate use of non-vitamin K antagonist oral anticoagulants in elderly Chinese patients with atrial fibrillation: A study protocol
por: Zhao, Shu-Juan, et al.
Publicado: (2022)

Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients
por: Zhou, Bo, et al.
Publicado: (2021)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
por: Maura, Géric, et al.
Publicado: (2019)

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
por: Shen, Nan-Nan, et al.
Publicado: (2020)

The Role of Patient-Specific Morphological Features of the Left Atrial Appendage on the Thromboembolic Risk Under Atrial Fibrillation
por: Musotto, Giulio, et al.
Publicado: (2022)

Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2
por: Trohman, Richard G., et al.
Publicado: (2023)

Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1
por: Trohman, Richard G., et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
por: Wulamiding, Kaisaier, et al.
Publicado: (2022)

Editorial: Venous thromboembolism and pregnancy
por: Tardy, Bernard, et al.
Publicado: (2022)

Venous Thromboembolism Risk Score and Pregnancy
por: Raia-Barjat, Tiphaine, et al.
Publicado: (2022)

Editorial: COVID-19 and Venous Thromboembolism
por: Yamashita, Yugo
Publicado: (2021)

Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
por: Gundlund, A, et al.
Publicado: (2019)

Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso
por: Yameogo, Aristide Relwendé, et al.
Publicado: (2016)

Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism
por: Colonna, Paolo, et al.
Publicado: (2017)

Vitamin K antagonists and cardiovascular calcification: A systematic review and meta-analysis
por: Kosciuszek, Nina D., et al.
Publicado: (2022)

Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy
por: Raia-Barjat, Tiphaine, et al.
Publicado: (2022)

Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
por: Tang, Lihong, et al.
Publicado: (2020)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
por: Zhu, Yong-Jian, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
por: Hong, Keun-Sik
Publicado: (2019)

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
por: Cases, Aleix, et al.
Publicado: (2021)

Clinical epidemiology of venous thromboembolic disease: An institutional registry
por: AlSheef, Mohammed, et al.
Publicado: (2022)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study
por: Cho, Iksung, et al.
Publicado: (2022)

Low-Voltage Area at the Anterior Wall of the Left Atrium Is Associated With Thromboembolism in Atrial Fibrillation Patients With a Low CHA(2)DS(2)-VA Score
por: Ding, Xiangwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_51k8vvojv6rhif74sap1j4049a